Showing 15 posts of 15 posts found.


Japan approves AstraZeneca’s Soliris for paediatric patients with gMG

August 24, 2023
Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris

AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …

AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation

June 26, 2023
Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris

UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …


Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria

January 8, 2020
Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris

Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …


Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019
Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …


Alexion’s Soliris almost entirely eliminates relapses in rare neuromyelitis optica spectrum disorder

September 26, 2018
Research and Development Alexion, neuromyelitis optica spectrum disorder, pharma, rare disease, soliris

Alexion has revealed new Phase 3 findings for Soliris (eculizumab), showing the drug met its primary endpoint in the treatment …


Alexion goes back to roots with Complement deal

June 11, 2018
Manufacturing and Production, Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris

Alexion has made a lot of money from investing in the science behind complement inhibitors – C5 inhibitor, Soliris, has …


Investigational Alexion drug proves non-inferior to Soliris in rare blood disease

April 27, 2018
Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris

Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …

Alexion moves to bolster patent protection of Soliris

August 17, 2017
Sales and Marketing Alexion, biotech, drugs, pharma, pharmaceutical, soliris

Soliris brought in net sales of $2.8 billion last year for Alexion, meaning it accounted for close to 90% of …


Alexion to challenge Canadian price of Soliris in court

September 28, 2015
Sales and Marketing Alexion, Canada, Drug pricing, Patented Medicine Prices Review Board, eculizumab, soliris

Alexion Pharmaceuticals is taking the Canadian government to court for its attempt to lower the price of the rare disease …

Alexion plans big expansion in Ireland

May 12, 2015
Manufacturing and Production, Sales and Marketing Alexion, Dublin, Ireland, soliris

Alexion Pharmaceuticals is significantly expanding its operations in Ireland by building the US firm’s first ever biologics manufacturing facility outside …

Soliris image

NICE approves world’s most expensive drug

January 28, 2015
Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris

The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …

Soliris image

NHS to get world’s most expensive drug

November 27, 2014
Sales and Marketing Alexion, NICE, aHUS, beauchamp, blood, eculizumab, soliris

UK health watchdog NICE has recommended Alexion’s Soliris for patients with the rare disease atypical haemolytic uremic syndrome (aHUS).  Soliris …


NHS needs to understand drug costs better, says ABPI

April 10, 2014
Medical Communications, Research and Development, Sales and Marketing ABPI, AGNSS, Deepak Khanna, NICE, Stephen Whitehead, Tarceva, soliris

The UK healthcare system is at risk of failing to adopt new, personalised medicines and must be willing to pay …

Soliris image

Alexion ‘concerned’ over NICE draft

March 4, 2014
Sales and Marketing NICE, aHUS, alexia, blood, eculizumab, soliris

Alexion Pharmaceuticals UK has expressed ‘concern’ that NICE has not yet allowed its rare disease treatment Soliris to be formally …

Roche ‘considers’ Alexion bid

July 16, 2013
Research and Development, Sales and Marketing Alexion, Orphan, Roche, soliris

Speculation that Roche is considering a bid for rare disease specialist Alexion Pharmaceuticals has unleashed a flurry of comment – …

Latest content